Potential berberine effect in the insulin resistance prevention and type 2 diabetes treatment

[1] Rad S.Z., Rameshrad M., Hosseinzadeh H.: Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: A review. Iran J. Basic. Med. Sci., 2017; 20: 516-529Rad S.Z. Rameshrad M. Hosseinzadeh H. Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: A review Iran J. Basic. Med. Sci 2017 20 516 529Search in Google Scholar

[2] Wojciechowska I.: Berberys pospolity – roślina ozdobna i lecznicza. Kosmos. Problemy Nauk Biol., 2017; 66: 487-490Wojciechowska I. Berberys pospolity – roślina ozdobna i lecznicza Kosmos. Problemy Nauk Biol 2017 66 487 490Search in Google Scholar

[3] Yu Y., Liu L., Wang X., Liu X., Liu X., Xie L., Wang G.: Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem. Pharmacol., 2010; 79: 1000-1006Yu Y. Liu L. Wang X. Liu X. Liu X. Xie L. Wang G. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies Biochem. Pharmacol 2010 79 1000 100610.1016/j.bcp.2009.11.01719945441Search in Google Scholar

[4] Zhang H., Wei J., Xue R., Wu J.D., Zhao W., Wang Z.Z., Wang S.K., Zhou Z.X., Song D.Q., Wang Y.M. i wsp.: Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 2010; 59: 285-292Zhang H. Wei J. Xue R. Wu J.D. Zhao W. Wang Z.Z. Wang S.K. Zhou Z.X. Song D.Q. Wang Y.M. i wsp. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression Metabolism 2010 59 285 29210.1016/j.metabol.2009.07.02919800084Search in Google Scholar

[5] Xing L.J., Zhang L., Liu T., Hua Y.Q., Zheng P.Y., Ji G.: Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in non-alcoholic fatty liver disease (NAFLD) rat liver. Eur. J. Pharmacol., 2011; 668: 467-471Xing L.J. Zhang L. Liu T. Hua Y.Q. Zheng P.Y. Ji G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in non-alcoholic fatty liver disease (NAFLD) rat liver Eur. J. Pharmacol 2011 668 467 47110.1016/j.ejphar.2011.07.03621839075Search in Google Scholar

[6] Xia X., Yan J., Shen Y., Tang K., Yin J., Zhang Y., Yang D., Liang H., Ye J., Weng J.: Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011; 6: e16556Xia X. Yan J. Shen Y. Tang K. Yin J. Zhang Y. Yang D. Liang H. Ye J. Weng J. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis PLoS One 2011 6 e1655610.1371/journal.pone.0016556303339021304897Search in Google Scholar

[7] Abd El-Wahab A.E., Ghareeb D.A., Sarhan E.E., Abu-Serie M.M., El Demellawy M.A.: In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: Antioxidants, antiacetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement. Altern. Med., 2013; 13: 218Abd El-Wahab A.E. Ghareeb D.A. Sarhan E.E. Abu-Serie M.M. El Demellawy M.A. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: Antioxidants, antiacetylcholinesterase, anti-diabetic and anticancer effects BMC Complement. Altern. Med 2013 13 21810.1186/1472-6882-13-218401655024007270Search in Google Scholar

[8] Boudjelthia K., Hammadi K., Kouidri M., Djebli N.: Evaluation of antidiabetic activity of two plants Berberis vulgaris and Zygophyllum geslini. J. Phys. Chem. Biophys., 2017; 7: 236Boudjelthia K. Hammadi K. Kouidri M. Djebli N. Evaluation of antidiabetic activity of two plants Berberis vulgaris and Zygophyllum geslini J. Phys. Chem. Biophys 2017 7 23610.4172/2161-0398.1000236Search in Google Scholar

[9] Chakrabarti R., Bhavtaran S., Narendra P., Varghese N., Vanchhawng L., Shihabudeen M.S., Thirumurgan K.: Dipeptidyl peptidase-IV inhibitory activity of Berberisaristata. J. Nat. Prod., 2011; 4: 158-163Chakrabarti R. Bhavtaran S. Narendra P. Varghese N. Vanchhawng L. Shihabudeen M.S. Thirumurgan K. Dipeptidyl peptidase-IV inhibitory activity of Berberisaristata J. Nat. Prod 2011 4 158 163Search in Google Scholar

[10] Jiang S.J., Dong H., Li J.B., Xu L.J., Zou X., Wang K.F., Lu F.E., Yi P.: Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J. Gastroenterol., 2015; 21: 7777-7785Jiang S.J. Dong H. Li J.B. Xu L.J. Zou X. Wang K.F. Lu F.E. Yi P. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats World J. Gastroenterol 2015 21 7777 778510.3748/wjg.v21.i25.7777449196426167077Search in Google Scholar

[11] Furrianca M.C., Alvear M., Zambrano T., Fajardo V., Salazar L.A.: Hypoglycemic effect of Berberis microphylla G Forst root extract. Trop. J. Pharm. Res., 2017; 16: 2179-2184Furrianca M.C. Alvear M. Zambrano T. Fajardo V. Salazar L.A. Hypoglycemic effect of Berberis microphylla G Forst root extract Trop. J. Pharm. Res 2017 16 2179 218410.4314/tjpr.v16i9.19Search in Google Scholar

[12] Xu M., Xiao Y., Yin J., Hou W., Yu X., Shen L., Liu F., Wei L., Jia W.: Berberine promotes glucose consumption independently of AMP-activated protein kinase activation. PLoS One, 2014; 9: e103702Xu M. Xiao Y. Yin J. Hou W. Yu X. Shen L. Liu F. Wei L. Jia W. Berberine promotes glucose consumption independently of AMP-activated protein kinase activation PLoS One 2014 9 e10370210.1371/journal.pone.0103702411487425072399Search in Google Scholar

[13] Zhang H., Wang X., Wang T., Chen K., Wang H., Jia Q., Li Y.: Enhancement of berberine hypoglycemic activity by oligomeric proanthocyanidins. Molecules, 2018; 23: 3318Zhang H. Wang X. Wang T. Chen K. Wang H. Jia Q. Li Y. Enhancement of berberine hypoglycemic activity by oligomeric proanthocyanidins Molecules 2018 23 331810.3390/molecules23123318632125230558158Search in Google Scholar

[14] Liu D., Zhang Y., Liu Y., Hou L., Li S., Tian H., Zhao T.: Berberine modulates gut microbiota and reduces insulin resistance via the TLR4 signaling pathway. Exp. Clin. Endocrinol. Diabetes, 2018; 126: 513-520Liu D. Zhang Y. Liu Y. Hou L. Li S. Tian H. Zhao T. Berberine modulates gut microbiota and reduces insulin resistance via the TLR4 signaling pathway Exp. Clin. Endocrinol. Diabetes 2018 126 513 52010.1055/s-0043-12506629365334Search in Google Scholar

[15] Zhong Y., Jin J., Liu P., Song Y., Zhang H., Sheng L., Zhou H., Jiang B.: Berberine attenuates hyperglycemia by inhibiting the hepatic glucagon pathway in diabetic mice. Oxid. Med. Cell. Longev., 2020; 2020: 6210526Zhong Y. Jin J. Liu P. Song Y. Zhang H. Sheng L. Zhou H. Jiang B. Berberine attenuates hyperglycemia by inhibiting the hepatic glucagon pathway in diabetic mice Oxid. Med. Cell. Longev 2020 2020 621052610.1155/2020/6210526696161131976031Search in Google Scholar

[16] Liu L., Yu Y.L., Yang J.S, Li Y., Liu Y.W., Liang Y., Liu X.D., Xie L., Wang G.J.: Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn. Schmiedebergs. Arch. Pharmacol., 2010; 381: 371-381Liu L. Yu Y.L. Yang J.S Li Y. Liu Y.W. Liang Y. Liu X.D. Xie L. Wang G.J. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study Naunyn. Schmiedebergs. Arch. Pharmacol 2010 381 371 38110.1007/s00210-010-0502-020229011Search in Google Scholar

[17] Gong J., Hu M., Huang Z., Fang K., Wang D., Chen Q., Li J., Yang D., Zou X., Xu L. i wsp.: Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats. Front Pharmacol., 2017; 8: 42Gong J. Hu M. Huang Z. Fang K. Wang D. Chen Q. Li J. Yang D. Zou X. Xu L. i wsp. Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats Front Pharmacol 2017 8 4210.3389/fphar.2017.00042529045828217099Search in Google Scholar

[18] Zhang Q., Xiao X., Feng K., Wang T., Li W., Yuan T., Sun X., Sun Q., Xiang H., Wang H.: Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid. Based Complement. Alternat. Med., 2011; 2011: 924851Zhang Q. Xiao X. Feng K. Wang T. Li W. Yuan T. Sun X. Sun Q. Xiang H. Wang H. Berberine moderates glucose and lipid metabolism through multipathway mechanism Evid. Based Complement. Alternat. Med 2011 2011 92485110.1155/2011/924851295233420953398Search in Google Scholar

[19] Gomes A.P., Duarte F.V., Nunes P., Hubbard B.P., Teodoro J.S., Varela A.T., Jones J.G., Sinclair D.A., Palmeira C.M., Rolo A.P.: Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochem. Biophys. Acta, 2012; 1822: 185-195Gomes A.P. Duarte F.V. Nunes P. Hubbard B.P. Teodoro J.S. Varela A.T. Jones J.G. Sinclair D.A. Palmeira C.M. Rolo A.P. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis Biochem. Biophys. Acta 2012 1822 185 19510.1016/j.bbadis.2011.10.008336668822027215Search in Google Scholar

[20] Mi J., He W., Lv J., Zhuang K., Huang H., Quan S.: Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats. Diabetes Metab. Syndr. Obes., 2019; 12: 1717-1725Mi J. He W. Lv J. Zhuang K. Huang H. Quan S. Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats Diabetes Metab. Syndr. Obes 2019 12 1717 172510.2147/DMSO.S211188673198831564939Search in Google Scholar

[21] Chen C., Zhang Y., Huang C.: Berberine inhibits PTP1B activity and mimics insulin action. Biochem. Biophys. Res. Commun., 2010; 397: 543-547Chen C. Zhang Y. Huang C. Berberine inhibits PTP1B activity and mimics insulin action Biochem. Biophys. Res. Commun 2010 397 543 54710.1016/j.bbrc.2010.05.15320515652Search in Google Scholar

[22] Yang J., Yin J., Gao H., Xu L., Wang Y., Xu L., Li M.: Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid. Based Complement. Alternat. Med., 2012; 2012: 363845Yang J. Yin J. Gao H. Xu L. Wang Y. Xu L. Li M. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients Evid. Based Complement. Alternat. Med 2012 2012 36384510.1155/2012/363845331016522474499Search in Google Scholar

[23] Chang W., Zhang M., Li J., Meng Z., Wei S., Du H., Chen L., Hatch G.M.: Berberine improves insulin resistance in cardiomyocytes via activation of 5′-adenosine monophosphate-activated protein kinase. Metabolism, 2013; 62: 1159-1167Chang W. Zhang M. Li J. Meng Z. Wei S. Du H. Chen L. Hatch G.M. Berberine improves insulin resistance in cardiomyocytes via activation of 5′-adenosine monophosphate-activated protein kinase Metabolism 2013 62 1159 116710.1016/j.metabol.2013.02.00723537779Search in Google Scholar

[24] Zhang B., Pan Y., Xu L., Tang D., Dorfman R.G., Zhou Q., Yin Y., Li Y., Zhou L., Zhao S. i wsp.: Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine, 2018; 62: 576-587Zhang B. Pan Y. Xu L. Tang D. Dorfman R.G. Zhou Q. Yin Y. Li Y. Zhou L. Zhao S. i wsp. Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3 Endocrine 2018 62 576 58710.1007/s12020-018-1689-y30117113Search in Google Scholar

[25] Chen Y., Wang Y., Zhang J., Sun C., Lopez A.: Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endocrinol. 2011; 2011: 519371Chen Y. Wang Y. Zhang J. Sun C. Lopez A. Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance ISRN Endocrinol 2011 2011 51937110.5402/2011/519371326264622363882Search in Google Scholar

[26] Xue M., Yang M.X., Zhang W., Li X.M., Gao D.H., Ou Z.M., Li Z.P., Liu S.H., Li X.J., Yang S.Y.: Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int. J. Nanomedicine, 2013; 8: 4677-4687Xue M. Yang M.X. Zhang W. Li X.M. Gao D.H. Ou Z.M. Li Z.P. Liu S.H. Li X.J. Yang S.Y. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles Int. J. Nanomedicine 2013 8 4677 468710.2147/IJN.S51262386250924353417Search in Google Scholar

[27] Almani S.A., Memon I.A., Shaikh T.Z., Khoharo H.K., Ujjan I.: Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus. Iran J. Basic Med. Sci., 2017; 20: 511-515Almani S.A. Memon I.A. Shaikh T.Z. Khoharo H.K. Ujjan I. Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus Iran J. Basic Med. Sci 2017 20 511 515Search in Google Scholar

[28] Pérez-Rubio K.G., González-Ortiz M., Martínez-Abundis E., Robles-Cervantes J.A., Espiinel-Bermúdez M.C.: Effect of berberine administration on metabolic sydrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord., 2013; 11: 366-369Pérez-Rubio K.G. González-Ortiz M. Martínez-Abundis E. Robles-Cervantes J.A. Espiinel-Bermúdez M.C. Effect of berberine administration on metabolic sydrome, insulin sensitivity, and insulin secretion Metab. Syndr. Relat. Disord 2013 11 366 36910.1089/met.2012.018323808999Search in Google Scholar

[29] Chen L, Lu W, Li Y. Berberine ameliorates type 2 diabetes via modulation of Bifidobacterium species, tumor necrosis factor-α, and lipopolysaccharide. Int. J. Clin. Exp. Med., 2016; 9: 9365-9372Chen L Lu W Li Y Berberine ameliorates type 2 diabetes via modulation of Bifidobacterium species, tumor necrosis factor-α, and lipopolysaccharide Int. J. Clin. Exp. Med 2016 9 9365 9372Search in Google Scholar

[30] Memon M.A., Khan R.N., Riaz S., Ain Q.U., Ahmed M., Kumar N.: Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients. J. Res. Med. Sci., 2018; 23: 110Memon M.A. Khan R.N. Riaz S. Ain Q.U. Ahmed M. Kumar N. Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients J. Res. Med. Sci 2018 23 110Search in Google Scholar

[31] Sheng Z.X., Xie D.H.: Therapeutic effect of berberine on the levels of inflammatory factors in type 2 diabetic patients. New Med., 2010; 4: 177-180Sheng Z.X. Xie D.H. Therapeutic effect of berberine on the levels of inflammatory factors in type 2 diabetic patients New Med 2010 4 177 180Search in Google Scholar

[32] Cao C., Su M.: Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp. Ther. Med., 2019; 17: 3009-3014Cao C. Su M. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome Exp. Ther. Med 2019 17 3009 301410.3892/etm.2019.7295643423530936971Search in Google Scholar

[33] Shidfar F., Ebrahimi S.S., Hosseini S., Heydari I., Shidfar S., Hajhassani G.: The effects of Berberis vulgaris fruit extract on serum lipoproteins, apoB, apoA-I, homocysteine, glycemic control and total antioxidant capacity in type 2 diabetic patients. Iran J. Pharm. Res., 2012; 11: 643-652Shidfar F. Ebrahimi S.S. Hosseini S. Heydari I. Shidfar S. Hajhassani G. The effects of Berberis vulgaris fruit extract on serum lipoproteins, apoB, apoA-I, homocysteine, glycemic control and total antioxidant capacity in type 2 diabetic patients Iran J. Pharm. Res 2012 11 643 652Search in Google Scholar

[34] Di Pierro F., Villanova N., Agostini F., Marzocchi R., Soverini V., Marchesini G.: Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab. Syndr. Obes., 2012; 5: 213-217Di Pierro F. Villanova N. Agostini F. Marzocchi R. Soverini V. Marchesini G. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control Diabetes Metab. Syndr. Obes 2012 5 213 21710.2147/DMSO.S33718Search in Google Scholar

[35] Derosa G., Bonaventura A., Bianchi L., Romano D., D’Angelo A., Fogari E., Maffioli P.: Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J. Biol. Regul. Homeost. Agents, 2013; 27: 717-728Derosa G. Bonaventura A. Bianchi L. Romano D. D’Angelo A. Fogari E. Maffioli P. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients J. Biol. Regul. Homeost. Agents 2013 27 717 728Search in Google Scholar

[36] Di Pierro F., Bellone I., Rapacioli G., Putignano P.: Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab. Syndr. Obes, 2015; 8: 89-96Di Pierro F. Bellone I. Rapacioli G. Putignano P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins Diabetes Metab. Syndr. Obes 2015 8 89 9610.2147/DMSO.S78877Search in Google Scholar

[37] Guarino G., Strollo F., Carbone L., Della Corte T., Letizia M., Marino G., Gentile S.: Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Silybum marianum: A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J. Biol. Regul. Homeost. Agents, 2017; 31: 495-502Guarino G. Strollo F. Carbone L. Della Corte T. Letizia M. Marino G. Gentile S. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Silybum marianum: A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes J. Biol. Regul. Homeost. Agents 2017 31 495 502Search in Google Scholar

[38] Li M.F., Zhou X.M., Li X.L.: The effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): A meta-analysis and systematic review. Evid. Based Complement Alternat. Med., 2018; 2018: 2532935Li M.F. Zhou X.M. Li X.L. The effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): A meta-analysis and systematic review Evid. Based Complement Alternat. Med 2018 2018 253293510.1155/2018/2532935626124430538756Search in Google Scholar